An antibody cocktail from Regeneron has been approved by the FDA as the first treatment for Ebola, offering hope that a similar approach could be used to combat COVID-19.

Regeneron’s antibody cocktail is the latest COVID-19 drug to receive Emergency Use Authorization in the US, becoming the first therapy of this kind to become available.

What lessons can be learnt from treating Trump? Why is his proclamation of Regeneron's unproven and experimental antibody ...

I had the opportunity to sit down with Dr. George Yancopoulos, Co-founder, President, and Chief Scientific Officer for Regeneron Pharmaceuticals ... receiving our antibody cocktail on a monthly ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Valued at a market cap of $82.9 billion, Regeneron Pharmaceuticals ... and Zaltrap and is also known for developing an antibody cocktail for COVID-19, called REGEN-COV. Companies valued at ...

Here is what is currently known about the drugs Trump has been taking to combat his illness: One of the first reported treatments Trump received was an experimental cocktail of two monoclonal ...

Regeneron specializes in antibody medicines ... trial last year that the study came to an early close. (The antibody cocktail, which is currently under review by the FDA, is being used to treat ...

Lab experiments on Regeneron pharmaceuticals' REGN-COV2 -- a 2 recombinant monoclonal antibody cocktail -- showed that casirivamab had lost some of its neutralising activity against the South ...

Regeneron also recently won FDA approval for Inmazeb, another antibody cocktail and the first-ever drug proved to be effective in treating Ebola. Those innovations have helped boost Regeneron’s ...

Roivant earns top recognition in the science and technology category of Fast Company's Best Workplaces for Innovators 2023. Best Workplaces for Innovators 2023: Sustainability Holcim earns top ...